Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1993 1
1997 2
1998 1
1999 1
2000 5
2001 3
2002 9
2003 19
2004 15
2005 22
2006 25
2007 24
2008 24
2009 30
2010 23
2011 44
2012 38
2013 31
2014 33
2015 38
2016 45
2017 51
2018 45
2019 55
2020 31
2021 39
2022 44
2023 51
2024 12

Text availability

Article attribute

Article type

Publication date

Search Results

671 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for lipitor m
Your search for glipixor-m retrieved no results
Polypill Strategy in Secondary Cardiovascular Prevention.
Castellano JM, Pocock SJ, Bhatt DL, Quesada AJ, Owen R, Fernandez-Ortiz A, Sanchez PL, Marin Ortuño F, Vazquez Rodriguez JM, Domingo-Fernández A, Lozano I, Roncaglioni MC, Baviera M, Foresta A, Ojeda-Fernandez L, Colivicchi F, Di Fusco SA, Doehner W, Meyer A, Schiele F, Ecarnot F, Linhart A, Lubanda JC, Barczi G, Merkely B, Ponikowski P, Kasprzak M, Fernandez Alvira JM, Andres V, Bueno H, Collier T, Van de Werf F, Perel P, Rodriguez-Manero M, Alonso Garcia A, Proietti M, Schoos MM, Simon T, Fernandez Ferro J, Lopez N, Beghi E, Bejot Y, Vivas D, Cordero A, Ibañez B, Fuster V; SECURE Investigators. Castellano JM, et al. N Engl J Med. 2022 Sep 15;387(11):967-977. doi: 10.1056/NEJMoa2208275. Epub 2022 Aug 26. N Engl J Med. 2022. PMID: 36018037 Clinical Trial.
The polypill treatment consisted of aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and atorvastatin (20 or 40 mg). The primary composite outcome was cardiovascular death, nonfatal type 1 myocardial infarction, nonfatal ischemic stroke, or urgent revascularization. ...CONCL …
The polypill treatment consisted of aspirin (100 mg), ramipril (2.5, 5, or 10 mg), and atorvastatin (20 or 40 mg). The primary compos …
Rosuvastatin versus atorvastatin treatment in adults with coronary artery disease: secondary analysis of the randomised LODESTAR trial.
Lee YJ, Hong SJ, Kang WC, Hong BK, Lee JY, Lee JB, Cho HJ, Yoon J, Lee SJ, Ahn CM, Kim JS, Kim BK, Ko YG, Choi D, Jang Y, Hong MK; LODESTAR investigators. Lee YJ, et al. BMJ. 2023 Oct 18;383:e075837. doi: 10.1136/bmj-2023-075837. BMJ. 2023. PMID: 37852649 Free PMC article. Clinical Trial.
OBJECTIVE: To compare the long term efficacy and safety of rosuvastatin with atorvastatin treatment in adults with coronary artery disease. DESIGN: Randomised, open label, multicentre trial. ...Mean daily dose of study drugs was 17.1 mg (standard deviation (SD) 5.2 mg) in …
OBJECTIVE: To compare the long term efficacy and safety of rosuvastatin with atorvastatin treatment in adults with coronary artery di …
Association of Rosuvastatin Use with Risk of Hematuria and Proteinuria.
Shin JI, Fine DM, Sang Y, Surapaneni A, Dunning SC, Inker LA, Nolin TD, Chang AR, Grams ME. Shin JI, et al. J Am Soc Nephrol. 2022 Sep;33(9):1767-1777. doi: 10.1681/ASN.2022020135. Epub 2022 Jul 19. J Am Soc Nephrol. 2022. PMID: 35853713 Free PMC article.
A substantial share (44%) of patients with eGFR <30 ml/min per 1.73 m(2) was prescribed high-dose rosuvastatin (20 or 40 mg daily). ...Among patients with eGFR <30 ml/min per 1.73 m(2), 44% were prescribed a rosuvastatin daily dose exceeding the FDA's recommen …
A substantial share (44%) of patients with eGFR <30 ml/min per 1.73 m(2) was prescribed high-dose rosuvastatin (20 or 40 mg daily) …
AIBP-mediated cholesterol efflux instructs hematopoietic stem and progenitor cell fate.
Gu Q, Yang X, Lv J, Zhang J, Xia B, Kim JD, Wang R, Xiong F, Meng S, Clements TP, Tandon B, Wagner DS, Diaz MF, Wenzel PL, Miller YI, Traver D, Cooke JP, Li W, Zon LI, Chen K, Bai Y, Fang L. Gu Q, et al. Science. 2019 Mar 8;363(6431):1085-1088. doi: 10.1126/science.aav1749. Epub 2019 Jan 31. Science. 2019. PMID: 30705153 Free PMC article.
Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update.
Schachter M. Schachter M. Fundam Clin Pharmacol. 2005 Feb;19(1):117-25. doi: 10.1111/j.1472-8206.2004.00299.x. Fundam Clin Pharmacol. 2005. PMID: 15660968 Review.
Atorvastatin, simvastatin, lovastatin, fluvastatin, cerivastatin and pitavastatin are relatively lipophilic compounds. ...Clinical studies have demonstrated rosuvastatin to be the most effective for reducing low-density lipoprotein cholesterol, followed by atorvastatin
Atorvastatin, simvastatin, lovastatin, fluvastatin, cerivastatin and pitavastatin are relatively lipophilic compounds. ...Clinical st
A 52-week placebo-controlled trial of evolocumab in hyperlipidemia.
Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, Monsalvo ML, Tsirtsonis K, Kim JB, Scott R, Wasserman SM, Stein EA; DESCARTES Investigators. Blom DJ, et al. N Engl J Med. 2014 May 8;370(19):1809-19. doi: 10.1056/NEJMoa1316222. Epub 2014 Mar 29. N Engl J Med. 2014. PMID: 24678979 Free article. Clinical Trial.
On the basis of this classification, patients were started on background lipid-lowering therapy with diet alone or diet plus atorvastatin at a dose of 10 mg daily, atorvastatin at a dose of 80 mg daily, or atorvastatin at a dose of 80 mg daily plus ezetimibe …
On the basis of this classification, patients were started on background lipid-lowering therapy with diet alone or diet plus atorvastatin
Pravastatin for lowering lipids.
Adams SP, Alaeiilkhchi N, Tasnim S, Wright JM. Adams SP, et al. Cochrane Database Syst Rev. 2023 Sep 18;9(9):CD013673. doi: 10.1002/14651858.CD013673.pub2. Cochrane Database Syst Rev. 2023. PMID: 37721222 Review.
This represented a dose-response slope that was less than the other studied statins: atorvastatin, rosuvastatin, fluvastatin, pitavastatin and cerivastatin. From other systematic reviews we conducted on statins for its effect to reduce LDL cholesterol, pravastatin is simil …
This represented a dose-response slope that was less than the other studied statins: atorvastatin, rosuvastatin, fluvastatin, pitavas …
Atorvastatin versus Placebo in ICU Patients with COVID-19: Ninety-day Results of the INSPIRATION-S Trial.
Talasaz AH, Sadeghipour P, Bakhshandeh H, Sharif-Kashani B, Rashidi F, Beigmohammadi MT, Moghadam KG, Rezaian S, Dabbagh A, Sezavar SH, Farrokhpour M, Abedini A, Aliannejad R, Riahi T, Yadollahzadeh M, Lookzadeh S, Rezaeifar P, Matin S, Tahamtan O, Mohammadi K, Zoghi E, Rahmani H, Hosseini SH, Mousavian SM, Abri H, Sadeghipour P, Baghizadeh E, Rafiee F, Jamalkhani S, Amin A, Mohebbi B, Parhizgar SE, Soleimanzadeh M, Aghakouchakzadeh M, Eslami V, Payandemehr P, Khalili H, Talakoob H, Tojari T, Shafaghi S, Tabrizi S, Kakavand H, Kashefizadeh A, Najafi A, Jimenez D, Gupta A, Madhavan MV, Sethi SS, Parikh SA, Monreal M, Hadavand N, Hajighasemi A, Ansarin K, Maleki M, Sadeghian S, Barco S, Siegerink B, Spatz ES, Piazza G, Kirtane AJ, Tassell BWV, Lip GYH, Klok FA, Goldhaber SZ, Stone GW, Krumholz HM, Bikdeli B. Talasaz AH, et al. Thromb Haemost. 2023 Jul;123(7):723-733. doi: 10.1055/a-2059-4844. Epub 2023 Mar 21. Thromb Haemost. 2023. PMID: 36944357 Clinical Trial.
Atorvastatin use was associated with improved 90-day functional status, although the upper bound CI crossed 1.0 (OR(ordinal): 0.64, 95% CI: 0.41-1.01, p = 0.05). CONCLUSION: Atorvastatin 20 mg compared with placebo did not significantly reduce the 90-day composite o
Atorvastatin use was associated with improved 90-day functional status, although the upper bound CI crossed 1.0 (OR(ordinal): 0.64, 9
Selected Statins as Dual Antiproliferative-Antiinflammatory Compounds.
Haj Hussein B, Kasabri V, Al-Hiari Y, Arabiyat S, Ikhmais B, Alalawi S, Al-Qirim T. Haj Hussein B, et al. Asian Pac J Cancer Prev. 2022 Dec 1;23(12):4047-4062. doi: 10.31557/APJCP.2022.23.12.4047. Asian Pac J Cancer Prev. 2022. PMID: 36579985 Free PMC article.
Atorvastatin was found of viability reduction IC50 value <20 M in HCT11650M in T47D, MCF7 and PANC1. Rosuvastatin had antineoplastic IC50 values (<50 M) in SW620<SW48050 M in remaining colorectal, breast and pancreatic cancer cell lines. ...
Atorvastatin was found of viability reduction IC50 value <20 M in HCT11650M in T47D, MCF7 and PANC1. Rosuvastatin had antin
671 results